Skip to main content
SpringerLink
Log in

A Perspective on Progress in Pharmacogenomics

  • Commentary
  • Published:
American Journal of Pharmacogenomics

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3(6): 361–70

    Article  PubMed  Google Scholar 

  2. Abbott A. With your genes?: take one of these three times a day. Nature 2003; 245: 760–2

    Article  Google Scholar 

  3. Bell J. The Human genome. In: Marinker M, Peckham M. editors. Clinical futures. London: BMJ Books, 1998

    Google Scholar 

  4. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm Res 2002; 19: 1179–787

    Article  Google Scholar 

  5. Lynch KR, O’Neill GP, Liu Q, et al. Characterisation of the human cysteinyl leukotriene Cys LT receptor. Nature 1999; 399: 789–93

    Article  PubMed  CAS  Google Scholar 

  6. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86–93

    Article  PubMed  CAS  Google Scholar 

  7. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 2002; 16(5): 317–24

    Article  PubMed  CAS  Google Scholar 

  8. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615–6

    Article  PubMed  CAS  Google Scholar 

  9. Bertilsson L, Dahl ML. Polymorphic drug oxidation. CNS Drugs 1996; 5: 200–23

    Article  CAS  Google Scholar 

  10. Higashi M, Veenstra D, Kondo LM, et al. Association between CYP2C9 genetic variants and anticocoagulant related outcomes during warfarin therapy. JAMA 2002; 287: 1690–8

    Article  PubMed  CAS  Google Scholar 

  11. Danzon P, Towse A. The economics of gene therapy and pharmacogenetics. Value Health 2002; 5(1): 5–13

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Clinical Neuropharmacology, Institute of Psychiatry, Kings College, De Crespigny Park, London, SE5 8AF, England

    Robert W. Kerwin

Authors
  1. Robert W. Kerwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert W. Kerwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerwin, R.W. A Perspective on Progress in Pharmacogenomics. Am J Pharmacogenomics 3, 371–373 (2003). https://doi.org/10.2165/00129785-200303060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129785-200303060-00003

Keywords

Search

Navigation